| Name | Title | Contact Details |
|---|
Eterna Therapeutics is developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. We and our strategic partners are advancing innovative nucleic acid and cell therapies that offer the hope of radically improving the health outcomes of patients with high unmet medical needs. We are committed to creating a world in which patients and their families have access to effective, life-changing treatments for serious illnesses.
Irvine Scientific is a Santa Ana, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Arrowhead Research Corporation is a biopharmaceutical company developing targeted RNAi therapeutics. The company is leveraging its proprietary Dynamic Polyconjugate delivery platform to develop targeted drugs based on the RNA interference mechanism that efficiently silences disease-causing genes. Arrowhead`s pipeline includes ARC-520 for chronic hepatitis B virus, ARC-AAT for liver disease associated with Alpha-1 antitrypsin deficiency, and partner-based programs in obesity and oncology.
Front Range Biosciences enables a grower to reduce crop loss due to pathogens, quickly sex a plant, and develop new strains of plants that have the most valuable commercial properties.
MicuRx mission is to discover and develop safer and more convenient antibiotics to combat drug-resistant bacterial infections. Multi-drug resistant (MDR) infections represent a major global threat to the public health, routinely forcing the use of antibiotics with high incidence of adverse effects. To combat resistant infections, physicians may increase dosing of antibiotics, or resort to less safe agents, pushing the safety envelope. Thus, healthcare providers and regulatory agencies increasingly face a difficult choice of balancing the risk of infection against unacceptably high adverse event rates from an effective but relatively toxic antibiotic. For example, in July 2016, FDA imposed a new labeling warning on the toxicity of fluoroquinolones, further restricting the use of this essential class, exemplified by anti-pseudomonal agent ciprofloxacin. Anti-MRSA agent linezolid (Zyvox®) is often used beyond its approved 14-day therapy, resulting in several myelosuppression-associated adverse effects listed in the black box warning for this important drug. MicuRx is addressing the critical need for effective but safer therapeutics by designing novel new compounds with reduced toxicity and adverse events while maintaining excellent clinical efficacy.